Uncategorized

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT Phase III clinical trial with LUMEVOQ®.

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial Read More »

BioInvent Issues Statement Confirming that it does not Hold Cash Deposits or Securities at Silicon Valley Bank

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, informed its shareholders that BioInvent does not hold cash deposits or securities at Silicon Valley Bank, or any other foreign bank.

BioInvent Issues Statement Confirming that it does not Hold Cash Deposits or Securities at Silicon Valley Bank Read More »

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Calliditas Therapeutics AB announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon delayed release capsules) versus placebo in patients with primary IgA nephropathy.

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy Read More »

Scroll to Top